# Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy

> **NCT04951921** · PHASE2 · COMPLETED · sponsor: **Chang Gung Memorial Hospital** · enrollment: 6 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Hyperpolarized 13C Pyruvate

## Key facts

- **NCT ID:** NCT04951921
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-15
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951921, "Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04951921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*